Table of Contents

1 Study Coverage

• 1.1 Indapamide Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Indapamide Market Size Growth Rate by Product
  • 1.4.2 1.25 mg Indapamide Tablets
  • 1.4.3 2.5 mg Indapamide Tablets
• 1.5 Market by End User
  • 1.5.1 Global Indapamide Market Size Growth Rate by End User
  • 1.5.2 High Blood Pressure Treatment
  • 1.5.3 Diuretic
  • 1.5.4 Hypertension Treatment
  • 1.5.5 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Indapamide Market Size
  • 2.1.1 Global Indapamide Revenue 2014-2025
  • 2.1.2 Global Indapamide Sales 2014-2025
• 2.2 Indapamide Growth Rate by Regions
  • 2.2.1 Global Indapamide Sales by Regions
  • 2.2.2 Global Indapamide Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Indapamide Sales by Manufacturers
  • 3.1.1 Indapamide Sales by Manufacturers
  • 3.1.2 Indapamide Sales Market Share by Manufacturers
  • 3.1.3 Global Indapamide Market Concentration Ratio (CR5 and HHI)
• 3.2 Indapamide Revenue by Manufacturers
  • 3.2.1 Indapamide Revenue by Manufacturers (2014-2019)
  • 3.2.2 Indapamide Revenue Share by Manufacturers (2014-2019)
• 3.3 Indapamide Price by Manufacturers
• 3.4 Indapamide Manufacturing Base Distribution, Product Types
  • 3.4.1 Indapamide Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Indapamide Product Type
  • 3.4.3 Date of International Manufacturers Enter into Indapamide Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Indapamide Sales by Product
• 4.2 Global Indapamide Revenue by Product
• 4.3 Indapamide Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Indapamide Breakdown Data by End User

6 North America

• 6.1 North America Indapamide by Countries
  • 6.1.1 North America Indapamide Sales by Countries
  • 6.1.2 North America Indapamide Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Indapamide by Product
• 6.3 North America Indapamide by End User

7 Europe

• 7.1 Europe Indapamide by Countries
  • 7.1.1 Europe Indapamide Sales by Countries
  • 7.1.2 Europe Indapamide Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Indapamide by Product
• 7.3 Europe Indapamide by End User

8 Asia Pacific

• 8.1 Asia Pacific Indapamide by Countries
  • 8.1.1 Asia Pacific Indapamide Sales by Countries
  • 8.1.2 Asia Pacific Indapamide Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Indapamide by Product
• 8.3 Asia Pacific Indapamide by End User

9 Central & South America

• 9.1 Central & South America Indapamide by Countries
  • 9.1.1 Central & South America Indapamide Sales by Countries
  • 9.1.2 Central & South America Indapamide Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Indapamide by Product
• 9.3 Central & South America Indapamide by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Indapamide by Countries
  • 10.1.1 Middle East and Africa Indapamide Sales by Countries
  • 10.1.2 Middle East and Africa Indapamide Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Indapamide by Product
• 10.3 Middle East and Africa Indapamide by End User

11 Company Profiles

• 11.1 Servier
  • 11.1.1 Servier Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Servier Indapamide Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Servier Indapamide Products Offered
  • 11.1.5 Servier Recent Development
• 11.2 Cigna
  • 11.2.1 Cigna Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Cigna Indapamide Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Cigna Indapamide Products Offered
  • 11.2.5 Cigna Recent Development
• 11.3 ANI Pharma
  • 11.3.1 ANI Pharma Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 ANI Pharma Indapamide Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 ANI Pharma Indapamide Products Offered
  • 11.3.5 ANI Pharma Recent Development
• 11.4 Mylan
  • 11.4.1 Mylan Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Mylan Indapamide Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Mylan Indapamide Products Offered
  • 11.4.5 Mylan Recent Development
• 11.5 Teva
  • 11.5.1 Teva Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Teva Indapamide Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Teva Indapamide Products Offered
  • 11.5.5 Teva Recent Development
• 11.6 Shandong Yinfeida Pharmaceutical
  • 11.6.1 Shandong Yinfeida Pharmaceutical Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Shandong Yinfeida Pharmaceutical Indapamide Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Shandong Yinfeida Pharmaceutical Indapamide Products Offered
  • 11.6.5 Shandong Yinfeida Pharmaceutical Recent Development
• 11.7 Taj Pharmaceuticals
  • 11.7.1 Taj Pharmaceuticals Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Taj Pharmaceuticals Indapamide Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Taj Pharmaceuticals Indapamide Products Offered
  • 11.7.5 Taj Pharmaceuticals Recent Development
• 11.8 Supra Chemicals
  • 11.8.1 Supra Chemicals Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Supra Chemicals Indapamide Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Supra Chemicals Indapamide Products Offered
  • 11.8.5 Supra Chemicals Recent Development
• 11.9 Glenmark Pharmaceuticals
  • 11.9.1 Glenmark Pharmaceuticals Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Glenmark Pharmaceuticals Indapamide Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Glenmark Pharmaceuticals Indapamide Products Offered
  • 11.9.5 Glenmark Pharmaceuticals Recent Development
• 11.10 Suzhou Lixinpharm
  • 11.10.1 Suzhou Lixinpharm Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Suzhou Lixinpharm Indapamide Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Suzhou Lixinpharm Indapamide Products Offered
  • 11.10.5 Suzhou Lixinpharm Recent Development
• 11.11 Lisheng Pharma
• 11.12 Apeloa Kangyu

12 Future Forecast

• 12.1 Indapamide Market Forecast by Regions
  • 12.1.1 Global Indapamide Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Indapamide Revenue Forecast by Regions 2019-2025
• 12.2 Indapamide Market Forecast by Product
  • 12.2.1 Global Indapamide Sales Forecast by Product 2019-2025
  • 12.2.2 Global Indapamide Revenue Forecast by Product 2019-2025
• 12.3 Indapamide Market Forecast by End User
• 12.4 North America Indapamide Forecast
• 12.5 Europe Indapamide Forecast
• 12.6 Asia Pacific Indapamide Forecast
• 12.7 Central & South America Indapamide Forecast
• 12.8 Middle East and Africa Indapamide Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Indapamide Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

The global Indapamide market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Indapamide market based on company, product type, end user and key regions.

This report studies the global market size of Indapamide in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Indapamide in these regions.
This research report categorizes the global Indapamide market by top players/brands, region, type and end user. This report also studies the global Indapamide market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Servier
Cigna
ANI Pharma
Mylan
Teva
Shandong Yinfeida Pharmaceutical
Taj Pharmaceuticals
Supra Chemicals
Glenmark Pharmaceuticals
Suzhou Lixinpharm
Lisheng Pharma
Apeloa Kangyu

Market size by Product
1.25 mg Indapamide Tablets
2.5 mg Indapamide Tablets
Market size by End User
High Blood Pressure Treatment
Diuretic
Hypertension Treatment
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Indapamide market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Indapamide market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Indapamide companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Indapamide submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Indapamide are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Indapamide market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.